Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It
represents a collaborative effort among the American Thoracic Society, Japanese …

Idiopathic pulmonary fibrosis (IPF) is a progressive clinical syndrome of unknown etiology and
fatal outcome. Currently available therapies are ineffective and associated with significant …

Study objectives Presently, surgical (open or thoracoscopic) lung biopsy (SLB) is the gold
standard for the diagnosis of new-onset idiopathic pulmonary fibrosis (IPF) and other …

Idiopathic pulmonary fibrosis (IPF) is an age-related disease featuring progressive lung
scarring. To elucidate the molecular basis of IPF, we performed exome sequencing of familial …

Background Despite Food and Drug Administration approval of 2 new drugs for idiopathic
pulmonary fibrosis (IPF), curative therapies remain elusive and mortality remains high. …

Current American Thoracic Society (ATS) standards promote the use of race and ethnicity-specific
reference equations for pulmonary function test (PFT) interpretation. There is rising …

FG-3019 is a fully human monoclonal antibody that interferes with the action of connective
tissue growth factor, a central mediator in the pathogenesis of fibrosis. This open-label phase …

Background: Well-designed clinical research needs to obtain information that is applicable
to the general population. However, most current studies fail to include substantial cohorts of …

Rationale Sarcoidosis is a granulomatous disease of unknown etiology. Many patients with
sarcoidosis demonstrate antigen-specific immunity to mycobacterial virulence factors. Th-17 …

Background Limited data are available on the association between clinically measured
disease severity markers and quality of life (QOL) in idiopathic pulmonary fibrosis (IPF). The …